logo
Share SHARE
FONT-SIZE Plus   Neg

Kennametal Posts Higher Q3 Profit; Revises 2012 View - Quick Facts

Kennametal Inc.'s (KMT) third-quarter net income attributable to the company grew to $75.50 million or $0.93 per share from $64.68 million or $0.77 per share last year. On average, 14 analysts polled by Thomson Reuters expected earnings per share of $0.93 for the quarter. Analysts' estimates typically exclude one-time items.

Sales were $696.4 million, compared with $615 million in the same quarter a year ago, as a result of organic growth of 8 percent and the impacts of acquisition of 4 percent and more business days of 3 percent, partially offset by unfavorable foreign currency impacts of 2 percent. Analysts estimated revenues of $686.32 million for the quarter.

Kennametal's Chairman, President and Chief Executive said, "The March quarter reflected ongoing global expansion which benefited many of our served end markets and geographies. Organic sales grew by 8 percent year over year, demonstrating the effectiveness of our strategies to continue to outperform industrial production and further gain market share."

Further, Kennametal updated its fiscal 2012 organic sales growth guidance to a range of 10 percent to 11 percent from its earlier range of 10 percent to 12 percent. Increased total sales growth guidance to a range of 16 percent to 17 percent from its previous estimate of 10 percent to 12 percent due to the acquisition of Deloro Stellite. The company also updated its fiscal 2012 earnings guidance to $3.80 to $3.90 per share from its earlier range of $3.70 to $3.90 per share.

Also, the company's board declared a regular quarterly cash dividend of $0.14 per share, payable May 23, 2012 to shareowners of record as of the close of business on May 8, 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Goldman Sachs downgraded the rating of retailer Target Corp. Thursday to sell from neutral over concerns about its increasing competition with e-commerce giant Amazon.com Inc. Target's price target was reduced to $67 from $77. It is expected that the retailer's efforts to compete with Amazon will result in sluggish sales and profits. Catabasis' phase II trial of Edasalonexent in boys affected by Duchenne muscular dystrophy is ongoing, and top-line results are anticipated in the first half of Q1 2017. American Express Co. (AXP) Thursday reported a drop in fourth-quarter profit, as revenues declined 4 percent due to absence of Costco portfolio while provisions for bad loans and marketing costs increased. Earnings fell short of Wall Street estimates, while revenues trumped expectations. New York-based...
comments powered by Disqus
Follow RTT